Health & Bio2 min read
Health & Bio
Food and Drug Administration Approves New Pill for Rare Disease Dermatomyositis
The Food and Drug Administration approved brepocitinib, sold as Lisraya, from Roivant Sciences and its subsidiary Priovant Therapeutics. The once-daily pill treats dermatomyositis, a rare autoimmune disease that causes…
The Food and Drug Administration on Thursday approved brepocitinib, a new medicine from biotechnology company Roivant Sciences and its subsidiary Priovant Therapeutics, to treat , a rare autoimmune disease. The drug will be sold under the brand name Lisraya and is taken as a pill once daily.
Dermatomyositis is marked by muscle weakness and a painful skin rash. The approval gives patients a new treatment option, alongside the current standard of care: high doses of steroids and other immune-suppressing drugs.
Roivant said dermatomyositis affects between 40,000 and 70,000 people in the United States.
Terms explained
The story so far
- FDA Approves Zanvastro, First Disease-Modifying Therapy for Alexander Disease
- Some Joints May Be Primed for Rheumatoid Arthritis Before Birth, Study Finds
- Russian Drugmaker and University Win Grant to Build CRISPR-Based Hepatitis B Cure
- Early Diagnosis and Treatment Are Key to Better Outcomes in Rheumatoid Arthritis, Review Finds
- Scientists Discover a Hidden Switch That Shuts Down Inflammation
- FDA Approves First Drug to Target Muscle Loss in Spinal Muscular Atrophy
- Food and Drug Administration Approves New Pill for Rare Disease Dermatomyositis
#dermatomyositis#FDA approval#Roivant Sciences#Priovant Therapeutics#brepocitinib#autoimmune disease#rare disease#biotech
Rate this story